TY - CHAP M1 - Book, Section TI - Osteoporosis A1 - Fitzgerald, Paul A. A2 - Papadakis, Maxine A. A2 - McPhee, Stephen J. A2 - Rabow, Michael W. A2 - McQuaid, Kenneth R. PY - 2022 T2 - Current Medical Diagnosis & Treatment 2022 AB - Key Clinical Updates in OsteoporosisDoses of vitamin D3 above 4000 international units daily in adults are generally not advised (except in patients with intestinal malabsorption), since gastrointestinal side effects or hypercalcemia may occur.Vitamin D should not be taken with topical calcipotriene to avoid hypercalcemia.The effects of denosumab on bone wane quickly after 6 months and patients can experience a dramatic increased risk of multiple vertebral fractures within 1–2 years following discontinuation of denosumab.Therefore, denosumab must be given on-schedule without drug holidays.Denosumab should not be discontinued without substituting another anti-resorptive agent (bisphosphonate, estradiol, or SERM) or other therapy. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1184697635 ER -